Table 2.
Baseline patient characteristics
| Baseline patient characteristics | Median (interquartile range) or no. (%) |
|---|---|
| Age, y | 48.6 (31.2-58.6) |
| Female sex | 477 (39) |
| Previous pregnancy, among female patients | 315 (66) |
| Previous platelet transfusion | 701 (57) |
| Previous RBC transfusion | 923 (75) |
| Primary diagnosis | |
| Acute leukemia | 544 (44) |
| Lymphoma | 259 (21) |
| Myeloma | 153 (12) |
| Chronic leukemia | 80 (7) |
| Myelodysplasia | 54 (4) |
| Solid tumor | 18 (1) |
| Other | 123 (10) |
| Treatment stratum | |
| Allogeneic transplantation | 505 (41) |
| Autologous/syngeneic transplantation | 426 (35) |
| Chemotherapy (nontransplantation therapy) for hematologic cancer | 293 (24) |
| Chemotherapy (nontransplantation therapy) for solid tumor | 7 (1) |
| Platelet count, × 103/μL | 38 (25-61) |
| Hemoglobin, g/dL | 9.8 (9.0-10.7) |
| Weight, kg | 78.1 (62.9-92.5) |
| Body surface area, m2 | 1.91 (1.69-2.08) |
| Platelet dose group | |
| LD | 396 (32) |
| MD | 412 (33) |
| HD | 423 (34) |
Baseline characteristics of the 1231 PLADO patients who received at least one platelet transfusion, but no HLA-selected platelet transfusions, while on study.
RBC indicates red blood cell; LD, low dose; MD, medium dose; and HD, high dose.